{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:31Z","timestamp":1789135951117,"version":"build-2803163510"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Shanghai Hospital Development Center Foundation","award":["SHDC22024204,"],"award-info":[{"award-number":["SHDC22024204,"]}]},{"name":"Shanghai Medicine and Health Development Foundation","award":["20221128"],"award-info":[{"award-number":["20221128"]}]},{"DOI":"10.13039\/501100009018","name":"Shanghai Municipal Human Resources and Social Security Bureau","doi-asserted-by":"crossref","award":["EK00000861"],"award-info":[{"award-number":["EK00000861"]}],"id":[{"id":"10.13039\/501100009018","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is a gap in the pharmacokinetic data on tacrolimus in children with juvenile dermatomyositis (JDM). This study aimed to develop a population pharmacokinetics (PopPK) model for tacrolimus in patients with JDM and formulate model-based recommended dosing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The PopPK model for tacrolimus was retrospectively developed in 31 children with JDM using nonlinear mixed-effects modeling. The trough concentrations of tacrolimus at different doses were simulated using the Monte Carlo method in children with different body weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The one-compartment model with first-order absorption and elimination best described the pharmacokinetic data of tacrolimus. In the final model, body weight and concomitant use of voriconazole (VRC) significantly affected the apparent clearance (CL\/F) of tacrolimus. The calculation of interindividual clearance was performed as follows: 12.635 \u00d7 (WT\/33.5)\n                      <jats:sup>0.296<\/jats:sup>\n                      \u00d7 (1\u22120.426 \u00d7 VRC). The tacrolimus CL\/F ratio in children with JDM was 1:0.574 between those without VRC coadministration and those with VRC coadministration at equivalent body weights. For patients with JDM and body weights of 10\u201320, 20\u201330, 30\u201340, and 40\u201360 kg, the recommended initial doses of tacrolimus without the combined use of VRC were 0.12, 0.08, 0.06, and 0.05 mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7d\n                      <jats:sup>\u22121<\/jats:sup>\n                      (q12h), respectively; the recommended initial doses of tacrolimus with the combined use of VRC were 0.07, 0.05, 0.04, and 0.03 mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7d\n                      <jats:sup>\u22121<\/jats:sup>\n                      (q12h), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This is the first study to establish a PopPK model for tacrolimus. Drug dosage regimens devised on the basis of this model provide evidence-based recommendations for patients with JDM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001491","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:00:18Z","timestamp":1781611218000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics and Initial Dosage Recommendation of Tacrolimus in Children with Juvenile Dermatomyositis"],"prefix":"10.1097","volume":"48","author":[{"given":"Zhang","family":"Yanping","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China;"},{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Yunnan University, Kunming, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Dan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Guangfei","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Mingqing","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Kunshan Maternity and Children's Health Care Hospital, Children's Hospital of Fudan University Kunshan Branch, Kunshan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Bin","sequence":"additional","affiliation":[{"name":"Kunshan Maternity and Children's Health Care Hospital, Kunshan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"Juan","sequence":"additional","affiliation":[{"name":"Department of Outpatient, Kunshan Maternity and Children's Health Care Hospital, Kunshan, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhiping","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China;"},{"name":"Department of Clinical Pharmacy, Kunshan Maternity and Children's Health Care Hospital, Children's Hospital of Fudan University Kunshan Branch, Kunshan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.40060","article-title":"2016 American College of Rheumatology (ACR) - European League against Rheumatism (EULAR) criteria for minimal, moderate and major clinical response for juvenile dermatomyositis: an international myositis assessment and clinical studies group\/paediatric rheumatology international trials organisation collaborative initiative","volume":"69","author":"Rider","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol."},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children's arthritis and rheumatology research alliance consensus conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res."},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14397595.2020.1718866","article-title":"Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-update","volume":"30","author":"Kobayashi","year":"2020","journal-title":"Mod Rheumatol."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/TP.0000000000003350","article-title":"Thirty years of tacrolimus in clinical practice","volume":"105","author":"Ong","year":"2021","journal-title":"Transplantation"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10067-008-0973-2","article-title":"Treatment of refractory juvenile dermatomyositis with tacrolimus","volume":"27","author":"Hassan","year":"2008","journal-title":"Clin Rheumatol."},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin a to treat polymyositis\/dermatomyositis-associated ILD:A randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejim.2023.01.018","article-title":"The efficacy and safety of tacrolimus in patients with dermatomyositis\/polymyositis: a meta-analysis and systematic review","volume":"110","author":"Liao","year":"2023","journal-title":"Eur J Intern Med."},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/jcpt.13072","article-title":"Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule","volume":"45","author":"Chen","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"R14-20260911","first-page":"4653","article-title":"Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: initial dosage recommendations","volume":"18","author":"Wang","year":"2019","journal-title":"Exp Ther Med."},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/bcp.16132","article-title":"Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants","volume":"91","author":"Banda","year":"2025","journal-title":"Br J Clin Pharmacol."},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00003088-200847040-00002","article-title":"Facilitation of drug evaluation in children by population methods and modelling","volume":"47","author":"Tod","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bcp.15909","article-title":"Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review","volume":"90","author":"Khamlek","year":"2024","journal-title":"Br J Clin Pharmacol."},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation","volume":"57","author":"Andrews","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/17512433.2020.1767592","article-title":"Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics","volume":"13","author":"Chen","year":"2020","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","article-title":"Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance","volume":"33","author":"Wallin","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"942129","DOI":"10.3389\/fphar.2022.942129","article-title":"Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: a combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol."},{"key":"R22-20260911","first-page":"178","article-title":"Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients","volume":"50","author":"Wang","year":"2020","journal-title":"Xenobiotica"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther."},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/00007890-200109270-00013","article-title":"Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants","volume":"72","author":"Staatz","year":"2001","journal-title":"Transplantation"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2125.2000.00288.x","article-title":"Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients","volume":"50","author":"Sam","year":"2000","journal-title":"Br J Clin Pharmacol."},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003088-200140010-00005","article-title":"Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy","volume":"40","author":"Garc\u00eda S\u00e1nchez","year":"2001","journal-title":"Clin Pharmacokinet."},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/jcpt.12828","article-title":"Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: a retrospective study","volume":"44","author":"Wang","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","article-title":"Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation","volume":"36","author":"Musuamba","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"891648","DOI":"10.3389\/fphar.2022.891648","article-title":"Population pharmacokinetics and initial dosage optimization of tacrolimus in pediatric hematopoietic stem cell transplant patients","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol."},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"R31-20260911","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12969-023-00933-5","article-title":"Lung infection or inflammation - a puzzling case of MDA-5 associated juvenile dermatomyositis","volume":"21","author":"Vuppala","year":"2023","journal-title":"Pediatr Rheumatol Online J."},{"key":"R32-20260911","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s12879-020-05341-8","article-title":"Next-generation sequencing technology for detecting pulmonary fungal infection in bronchoalveolar lavage fluid of a patient with dermatomyositis: a case report and literature review","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Infect Dis."},{"key":"R33-20260911","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.21037\/atm-21-4124","article-title":"Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med."},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/17425255.2016.1170808","article-title":"Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations","volume":"12","author":"Tang","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:33Z","timestamp":1789135233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001491","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2025-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}